Journal article
Paracetamol (acetaminophen) use, fracture and bone mineral density
LJ Williams, JA Pasco, MJ Henry, KM Sanders, GC Nicholson, MA Kotowicz, M Berk
Bone | Published : 2011
Abstract
Paracetamol is the most widely prescribed simple analgesic and antipyretic. It exerts its effects via cyclooxygenase and endocannabinoid pathways, which may affect signalling in bone cells and hence influence bone metabolism. Given the high rates of paracetamol use in the community and the evidence linking its mechanism of action to bone metabolism, we aimed to investigate the association between paracetamol use, fracture, and bone mineral density (BMD) in women participating in the Geelong Osteoporosis Study (GOS). Cases (n = 569) were women aged ≥ 50. years identified from radiological reports as having sustained a fracture between 1994 and 1996. Controls (n = 775) were women without fract..
View full abstractGrants
Awarded by Eli Lilly and Company
Funding Acknowledgements
[ "The study was funded by the National Health and Medical Research Council of Australia (#251638).", "Michael Berk has received Grant/Research Support from the Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma, Servier and Astra Zeneca. He has been a paid consultant for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Pfizer and a paid speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay and Wyeth." ]